PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15514976-6	2005	Our data suggest that levodopa-induced dyskinesia results from increased dopamine D(1) receptor-mediated transmission at the level of the direct pathway.	Levodopa	22-30	dopamine receptor D1	Homo sapiens	73-95	
31311029-1	2019	OBJECTIVE: Parkinson"s disease (PD) patients are usually treated with L-dopa and/or dopaminergic agonists, which act by binding five types of dopaminergic receptors (DRD1-DRD5).	Levodopa	70-76	dopamine receptor D1	Homo sapiens	166-170	
20808799-1	2010	BACKGROUND: In rodents, the development of dyskinesia produced by L-DOPA in the dopamine-depleted striatum occurs in response to increased dopamine D1 receptor-mediated activation of the cAMP - protein kinase A and of the Ras-extracellular signal-regulated kinase (ERK) signalling pathways.	Levodopa	66-72	dopamine receptor D1	Homo sapiens	139-159	
17350277-2	2007	While we recently demonstrated that levodopa-induced dyskinesia results from increased dopamine D(1) receptor-mediated transmission, we also questioned the possible role of subcellular localization of D(1) and D(2) receptors in mediating these effects as we previously showed that D(1) receptors undergo differential trafficking in striatal neurons of non-dyskinetic PD patients.	Levodopa	36-44	dopamine receptor D1	Homo sapiens	87-109	
32039920-1	2020	Dopamine receptor D1 modulates glutamatergic transmission in cortico-basal ganglia circuits and represents a major target of L-DOPA therapy in Parkinson"s disease.	Levodopa	125-131	dopamine receptor D1	Homo sapiens	0-20	
23041629-0	2012	PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.	Levodopa	27-33	dopamine receptor D1	Homo sapiens	53-73	
23041629-1	2012	L-DOPA-induced dyskinesia (LID), a detrimental consequence of dopamine replacement therapy for Parkinson"s disease, is associated with an alteration in dopamine D1 receptor (D1R) and glutamate receptor interactions.	Levodopa	0-6	dopamine receptor D1	Homo sapiens	152-172	
22028687-0	2011	L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.	Levodopa	0-6	dopamine receptor D1	Homo sapiens	92-112	
22028687-2	2011	Accumulating evidence indicates that l-DOPA-induced dyskinesia (LID) is primarily caused by the development of sensitized dopamine D1 receptor (D1R) transmission in the medium spiny neurons (MSNs) of the striatum.	Levodopa	37-43	dopamine receptor D1	Homo sapiens	122-142	
19028082-2	2009	Dopamine D(1) receptor agonists are potential alternative treatments to current therapies that employ L-DOPA, a dopamine precursor.	Levodopa	102-108	dopamine receptor D1	Homo sapiens	0-22	
17055481-2	2006	The gradual induction of dopamine D(1) receptor supersensitivity is known as a priming phenomenon, and this process is thought to underlie not only the appearance of vacuous chewing movements in humans with tardive dyskinesia, but also the onset of motor dyskinesias in L-dihydroxyphenylalanine (L-DOPA)-treated Parkinson"s disease patients.	Levodopa	270-294	dopamine receptor D1	Homo sapiens	25-47	
17055481-2	2006	The gradual induction of dopamine D(1) receptor supersensitivity is known as a priming phenomenon, and this process is thought to underlie not only the appearance of vacuous chewing movements in humans with tardive dyskinesia, but also the onset of motor dyskinesias in L-dihydroxyphenylalanine (L-DOPA)-treated Parkinson"s disease patients.	Levodopa	296-302	dopamine receptor D1	Homo sapiens	25-47	
2871516-0	1986	Differential effect of repeated treatment with L-dopa on dopamine-D1 or -D2 receptors.	Levodopa	47-53	dopamine receptor D1	Homo sapiens	57-85	
14705122-1	2004	The dopamine D(1) receptor is considered to participate in levodopa"s antiparkinsonian action and levodopa-induced dyskinesias.	Levodopa	59-67	dopamine receptor D1	Homo sapiens	4-26	
14705122-1	2004	The dopamine D(1) receptor is considered to participate in levodopa"s antiparkinsonian action and levodopa-induced dyskinesias.	Levodopa	98-106	dopamine receptor D1	Homo sapiens	4-26	
2138080-3	1990	Both dopamine D1 and D2 receptors are consistently elevated in Parkinson"s diseased striata from patients who have not been medicated with L-dopa pre-mortem.	Levodopa	139-145	dopamine receptor D1	Homo sapiens	5-33